Tau assemblies do not behave like independently acting prion-like particles in mouse neural tissue.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
12 03 2021
Historique:
received: 06 01 2021
accepted: 26 02 2021
entrez: 13 3 2021
pubmed: 14 3 2021
medline: 19 11 2021
Statut: epublish

Résumé

A fundamental property of infectious agents is their particulate nature: infectivity arises from independently-acting particles rather than as a result of collective action. Assemblies of the protein tau can exhibit seeding behaviour, potentially underlying the apparent spread of tau aggregation in many neurodegenerative diseases. Here we ask whether tau assemblies share with classical pathogens the characteristic of particulate behaviour. We used organotypic hippocampal slice cultures from P301S tau transgenic mice in order to precisely control the concentration of extracellular tau assemblies in neural tissue. Whilst untreated slices displayed no overt signs of pathology, exposure to recombinant tau assemblies could result in the formation of intraneuronal, hyperphosphorylated tau structures. However, seeding ability of tau assemblies did not titrate in a one-hit manner in neural tissue. The results suggest that seeding behaviour of tau arises at high concentrations, with implications for the interpretation of high-dose intracranial challenge experiments and the possible contribution of seeded aggregation to human disease.

Identifiants

pubmed: 33712082
doi: 10.1186/s40478-021-01141-6
pii: 10.1186/s40478-021-01141-6
pmc: PMC7953780
doi:

Substances chimiques

Prions 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41

Subventions

Organisme : Wellcome Trust
ID : 200594/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U105181010
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U105184326
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206248/Z/17/Z
Pays : United Kingdom

Références

J Neuropathol Exp Neurol. 2012 May;71(5):362-81
pubmed: 22487856
Am J Pathol. 2011 Feb;178(2):803-16
pubmed: 21281813
Acta Neuropathol. 2020 Jan;139(1):63-77
pubmed: 31616982
Science. 2015 Aug 7;349(6248):1255555
pubmed: 26250687
J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9
pubmed: 22002422
J Neurosci. 2013 Jan 16;33(3):1024-37
pubmed: 23325240
EMBO J. 2003 Feb 3;22(3):385-94
pubmed: 12554640
Ann Neurol. 2016 Sep;80(3):355-67
pubmed: 27351289
Acta Neuropathol. 2014 May;127(5):667-83
pubmed: 24531916
Nat Neurosci. 2018 Oct;21(10):1341-1349
pubmed: 30258241
J Neuroinflammation. 2019 May 18;16(1):106
pubmed: 31103036
Acta Neuropathol Commun. 2019 May 7;7(1):72
pubmed: 31064413
Neurol Ther. 2017 Jul;6(Suppl 1):15-24
pubmed: 28733960
J Biol Chem. 2009 May 8;284(19):12845-52
pubmed: 19282288
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Acta Neuropathol Commun. 2016 Nov 4;4(1):117
pubmed: 27809932
ACS Chem Neurosci. 2018 Jun 20;9(6):1276-1282
pubmed: 29590529
Front Neuroanat. 2019 Dec 19;13:99
pubmed: 31920568
Nat Cell Biol. 2009 Jul;11(7):909-13
pubmed: 19503072
Biochim Biophys Acta. 2001 Feb 14;1535(2):164-73
pubmed: 11342005
J Neurosci. 2002 Nov 1;22(21):9340-51
pubmed: 12417659
J Neurosci. 2011 Sep 14;31(37):13110-7
pubmed: 21917794
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Mol Neurodegener. 2017 Jan 13;12(1):5
pubmed: 28086931
Nat Protoc. 2006;1(3):1439-45
pubmed: 17406432
Mol Neurodegener. 2016 Jun 10;11(1):44
pubmed: 27287430
Elife. 2019 Feb 05;8:
pubmed: 30720432
Virology. 2006 Jul 5;350(2):493-500
pubmed: 16624363
J Physiol. 1978 Mar;276:353-67
pubmed: 650459
Curr Neuropharmacol. 2007 Mar;5(1):19-33
pubmed: 18615151
J Mol Neurosci. 2002 Dec;19(3):317-20
pubmed: 12540058
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8187-E8196
pubmed: 27911827
Mol Neurodegener. 2019 Dec 2;14(1):45
pubmed: 31791377
Cold Spring Harb Symp Quant Biol. 1953;18:273-9
pubmed: 13168995
Cell Death Dis. 2017 Mar 16;8(3):e2671
pubmed: 28300838
Neurosci Lett. 1995 Apr 21;189(3):167-9
pubmed: 7624036
Brain. 2009 May;132(Pt 5):1324-34
pubmed: 19321462
Acta Neuropathol. 2017 May;133(5):751-765
pubmed: 28293793
J Neurosci. 2017 Nov 22;37(47):11406-11423
pubmed: 29054878
Gene Ther. 1999 Jun;6(6):973-85
pubmed: 10455399
Clin Chem. 2001 Oct;47(10):1776-81
pubmed: 11568086
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):574-579
pubmed: 28049840

Auteurs

Lauren V C Miller (LVC)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK.

Aamir S Mukadam (AS)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK.

Claire S Durrant (CS)

John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.

Marina J Vaysburd (MJ)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.

Taxiarchis Katsinelos (T)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK.

Benjamin J Tuck (BJ)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK.

Sophie Sanford (S)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK.

Olivia Sheppard (O)

John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.

Claire Knox (C)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.

Shi Cheng (S)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK.

Leo C James (LC)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.

Michael P Coleman (MP)

John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.

William A McEwan (WA)

Department of Clinical Neurosciences, UK Dementia Research Institute at the University of Cambridge, Cambridge, UK. wm305@cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH